Hannah M Harris1, Jessica M Carpenter2, Jonathan R Black3, Todd A Smitherman4, Kenneth J Sufka5. 1. Department of Psychology, University of Mississippi, 207 Peabody Building, University, MS 38677, USA. Electronic address: hmharris@go.olemiss.edu. 2. Research Institute of Pharmaceutical Sciences, University of Mississippi, University, MS 38677, USA. Electronic address: jmc69554@uga.edu. 3. Department of Psychology, University of Mississippi, 207 Peabody Building, University, MS 38677, USA. Electronic address: jrblack@go.olemiss.edu. 4. Department of Psychology, University of Mississippi, 207 Peabody Building, University, MS 38677, USA. Electronic address: tasmithe@olemiss.edu. 5. Department of Psychology, University of Mississippi, 207 Peabody Building, University, MS 38677, USA; Research Institute of Pharmaceutical Sciences, University of Mississippi, University, MS 38677, USA. Electronic address: pysufka@olemiss.edu.
Abstract
BACKGROUND: Rodent models typically use a single nitroglycerin injection to induce migraine, yet migraine in clinical populations presents as recurrent episodes. Further, these models quantify behavioral endpoints that do not align with the clinical features of episodic migraine or migraine chronification and therefore may limit translational relevance. NEW METHOD: Rats received 5 nitroglycerin (10mg/kg/2ml), propylene glycol/ethanol vehicle, or saline injections every third day over 15days. Behavioral endpoints were assessed 110min post nitroglycerin administration and included time spent light/dark chambers for photophobia as well as activity, facial pain expressions, and tactile allodynia. RESULTS: Animals administered nitroglycerin displayed photophobia, decreased activity, and increased facial pain expression. Similar alterations in photophobia and activity were seen in the vehicle treated animals, but these tended to diminish by the 4th or 5th injection. The presentation of spontaneous tactile allodynia was observed in the nitroglycerin group by the 5th episode. COMPARISON WITH EXISTING METHODS: Most NTG migraine models entail a single NTG administration and quantification of evoked allodynia. This paradigm employs recurring NTG episodes and clinically-relevant measures of photophobia, hypoactivity and facial grimace endpoints as well as introduces a novel arena apparatus to quantify spontaneous allodynia. CONCLUSIONS: This repeated NTG procedure and endpoint measures aligns with the frequency and clinical presentation of episodic migraine and its chronification, respectively. Further, propylene glycol ethanol vehicle contributes to migraine endpoints.
BACKGROUND: Rodent models typically use a single nitroglycerin injection to induce migraine, yet migraine in clinical populations presents as recurrent episodes. Further, these models quantify behavioral endpoints that do not align with the clinical features of episodic migraine or migraine chronification and therefore may limit translational relevance. NEW METHOD: Rats received 5 nitroglycerin (10mg/kg/2ml), propylene glycol/ethanol vehicle, or saline injections every third day over 15days. Behavioral endpoints were assessed 110min post nitroglycerin administration and included time spent light/dark chambers for photophobia as well as activity, facial pain expressions, and tactile allodynia. RESULTS: Animals administered nitroglycerin displayed photophobia, decreased activity, and increased facial pain expression. Similar alterations in photophobia and activity were seen in the vehicle treated animals, but these tended to diminish by the 4th or 5th injection. The presentation of spontaneous tactile allodynia was observed in the nitroglycerin group by the 5th episode. COMPARISON WITH EXISTING METHODS: Most NTG migraine models entail a single NTG administration and quantification of evoked allodynia. This paradigm employs recurring NTG episodes and clinically-relevant measures of photophobia, hypoactivity and facial grimace endpoints as well as introduces a novel arena apparatus to quantify spontaneous allodynia. CONCLUSIONS: This repeated NTG procedure and endpoint measures aligns with the frequency and clinical presentation of episodic migraine and its chronification, respectively. Further, propylene glycol ethanol vehicle contributes to migraine endpoints.
Authors: Krishna D. B. Anapindi; Ning Yang; Elena V Romanova; Stanislav S Rubakhin; Alycia Tipton; Isaac Dripps; Zoie Sheets; Jonathan V Sweedler; Amynah A Pradhan Journal: Mol Cell Proteomics Date: 2019-10-24 Impact factor: 5.911
Authors: Pi-Chuan Fan; Tzu-Hsuan Lai; Chia Chun Hor; Ming Tatt Lee; Pokai Huang; Werner Sieghart; Margot Ernst; Daniel E Knutson; James Cook; Lih-Chu Chiou Journal: Neuropharmacology Date: 2018-07-21 Impact factor: 5.250
Authors: Hung-Ruei Tzeng; Ming Tatt Lee; Pi-Chuan Fan; Daniel E Knutson; Tzu-Hsuan Lai; Werner Sieghart; James Cook; Lih-Chu Chiou Journal: Neurotherapeutics Date: 2020-10-27 Impact factor: 7.620
Authors: Brandon J Rea; Anne-Sophie Wattiez; Jayme S Waite; William C Castonguay; Chantel M Schmidt; Aaron M Fairbanks; Bennett R Robertson; Cameron J Brown; Bianca N Mason; Maria-Cristina Moldovan-Loomis; Leon F Garcia-Martinez; Pieter Poolman; Johannes Ledolter; Randy H Kardon; Levi P Sowers; Andrew F Russo Journal: Pain Date: 2018-11 Impact factor: 7.926